Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer


*Corresponding authors. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA (M. Galsky); Icahn Institute for Genomics and Multiscale Biology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA (J. Zhu).
E-mail addresses: jun.zhu@mssm.edu (J. Zhu), matthew.galsky@mssm.edu (M.D. Galsky).

EU-ACME www.eu-acme.org/europeurology

Please visit www.eu-acme.org/europeurology to answer questions on-line. The EU-ACME credits will then be attributed automatically.

Abstract

Prior studies have demonstrated that fibroblast receptor 3 (FGFR3)-mutant urothelial cancers (UCs) are associated with decreased T-cell infiltration. As FGFR3 mutations are enriched in luminal-like UC and luminal-like UC has been shown to be relatively less responsive to PD-1/PD-L1 inhibition (checkpoint inhibition [CPI]), these data have led to the speculation that FGFR3 mutations may be causally related to poor T-cell infiltration and that UC patients harboring FGFR3 mutations may be suboptimal candidates for CPI. Using data derived from two clinical trials exploring CPI in metastatic UC, we demonstrate no statistically significant difference in response rates in patients with FGFR3-mutant versus wild-type UC. We present hypothesis-generating data, suggesting that similar response rates may be explained by a "balancing out" of previously identified independent positive and negative predictors of CPI sensitivity; that is, compared with FGFR3 wild-type UC, FGFR3-mutant UC is associated with a similar tumor mutational burden, lower T-cell infiltration, but also lower stromal/transforming growth factor beta (TGF-β) signals. Based on our findings, FGFR3 mutation status is not a biomarker of resistance to CPI. Indeed, the single-agent activity of both FGFR3 inhibitors and CPI in FGFR3-mutant UC, and potential non-cross resistance provide a strong pragmatic rationale for combination approaches.

Patient summary: In this report, we examined the impact of a mutated gene found in a subset of urothelial cancers on response to treatment with immunotherapy. We found that patients with tumors harboring mutations in the gene FGFR3 respond to immunotherapy similarly to patients without such mutations.

© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Immune checkpoint inhibition (CPI) has changed the landscape of treatment for metastatic urothelial cancer (mUC). However, a minority of patients respond to treatment, prompting the pursuit of biomarkers and mechanisms underlying resistance to guide combination approaches. Prior studies have shown that luminal I, or luminal papillary, urothelial cancer (UC) harbors lower T-cell infiltration compared with other subtypes, and is also associated with lower response rates with CPI [1,2]. Further, an in silico analysis previously reported a correlation between fibroblast receptor 3 (FGFR3) alterations and decreased T-cell infiltration [3]. As FGFR3 mutations (mFGFR3) are enriched in luminal UC, these data have led to the speculation that mFGFR3 may causally be related to poor T-cell infiltration. These observations have further fueled the conjecture that UC patients harboring mFGFR3 may be suboptimal candidates for CPI and have stimulated interest in combining CPI with FGFR3 inhibition as a means of overcoming CPI resistance.

We used the IMVigor 210 cohorts 1 and 2, a phase 2 trial exploring the PD-L1 inhibitor atezolizumab in patients with mUC, to assess the association between mFGFR3 and response to CPI [4]. The characteristics of IMVigor 210 have been described [4] and cohort characteristics are summarized in Supplementary Table 1. Hybrid capture-based next-generation sequencing data were available for 274 patients, among whom 49 had tumors harboring mFGFR3. There was no statistically significant difference in objective response rate with CPI or overall survival (OS) in patients with and without mFGFR3 in an analysis combining IMVigor 210 cohorts 1 and 2 (Fig. 1, Supplementary Table 2, and Supplementary Figs. 1 and 2), or when cohorts 1 and 2 were analyzed separately (Supplementary Fig. 3). We confirmed these findings in a second cohort utilizing whole exome sequencing data from CheckMate 275 [2], a single-arm phase 2 trial exploring the PD-1 inhibitor nivolumab in patients with mUC (Fig. 1, Supplementary material, Supplementary Table 1, and Supplementary Figs. 1 and 2).

We sought to reconcile our observations from these two clinical trial cohorts with prior observations correlating FGFR3 alterations with decreased T-cell infiltration. We first focused on FGFR3 gene expression because (1) prior studies correlated increased FGFR3 gene expression, along with mutations, with decreased T-cell infiltration [3] and (2) FGFR3 gene expression may encompass other mechanisms of increased FGFR3 signaling (e.g., amplifications, gene fusions) [5]. We confirmed that mFGFR3 was associated with increased FGFR3 gene expression compared with wild-type (WT) UC in the IMVigor 210 cohort (Supplementary Fig. 4). Consistent with prior studies, FGFR3 expression, or mFGFR3, was also negatively correlated with a T-cell gene signature (Supplementary Fig. 5 and Fig. 2). However, there was no statistically significant difference in response rates or OS with CPI among groups separated based on FGFR3 gene expression (Supplementary Figs. 5 and 6).

High tumor mutational burden (TMB) and T-cell gene signatures have been shown to be independently associated with response to CPI [4]. Further, our group and others have demonstrated that gene signatures derived from stromal elements are independently associated with CPI resistance [4,6]. We hypothesized that the lack of association between mFGFR3 and response to CPI, despite a negative correlation with T-cell infiltration, might be due to an imbalance in these other parameters. In the IMVigor 210 cohort, we found no statistically significant difference in TMB between mFGFR3 versus WT tumors; however, mFGFR3 tumors demonstrated significantly lower expression of a fibroblast TGF-β response signature or our epithelial to mesenchymal transition (EMT)/stromal signature versus WT tumors (Fig. 2). These findings support the concept that the lower T-cell infiltration in mFGFR3 tumors may be counterbalanced by a lower level of stromal-mediated immune suppression (Fig. 2) culminating in similar sensitivity to CPI in mFGFR3 and WT UC.

Given that FGFR3 inhibition is being pursued in combination with CPI in clinical trials, we sought to explore the spectrum of gene expression perturbed by mFGFR3 and FGFR3 inhibition in vitro. We obtained gene expression data for a panel of FGFR3 WT and mFGFR3 cell lines (Supplementary material) and also performed RNA sequencing of mFGFR3 cell lines (RT4, SW780, and MGHU3) after knocking down FGFR3 with two independent siRNAs (Supplementary Fig. 8) [7]. Compared with FGFR3 WT cells, mFGFR3 cells were associated with decreased expression of several immune-related genes particularly related to interferon response; conversely, expression of these genes increased with FGFR3 siRNA (Supplementary Fig. 9). FGFR3-mutant cells also demonstrated decreased expression of EMT- and TGF-β-related genes compared with WT cells; again, these gene signatures were increased in cells treated with FGFR3 siRNA (Supplementary Fig. 9). Similar to our data derived from human samples, these findings highlight the possibility of a complex relationship between the downstream impacts of mFGFR3 and antitumor immunity, and underscore the importance of considering the totality of the immunomodulatory effects of FGFR3 inhibition.

At least two retrospective analyses of patients with mFGFR3 UC enrolled in phase I/II trials of FGFR3 inhibitors have indicated infrequent responses to prior CPI in such patients [8,9]; however, given that the majority of patients do not respond to CPI, analyses centered on patients seeking enrollment on trials are at a risk of selection bias for CPI-progressing patients. An analysis of the IMVigor 211 phase 3 study previously revealed a relatively low response rate with atezolizumab in patients with mFGFR3 tumors, although with overlapping 95% confidence intervals for response rate compared with FGFR3 WT tumors [10].

There are potential limitations to our study. Despite confirming that FGFR3 alterations were associated with decreased inferred T-cell infiltration in the IMVigor dataset and decreased interferon response gene signatures in cell culture, these findings do not confirm a causal relationship. We lacked information on FGFR3 gene fusions, but probed the relationship between FGFR3 expression and response to CPI to try and encompass mechanisms of increased FGFR3 signaling beyond mutations. Our cell culture data are hypothesis generating, and the lack of a tumor microenvironment in such systems precludes a comprehensive
understanding of the immunomodulatory effects of FGFR3 inhibition and contextualization of changes in gene signatures largely ascribed to stromal cells in studies utilizing bulk human tumor transcriptome data (ie, EMT, TGF-β). However, we hypothesize that cross-talk likely exists between the epithelial and stromal compartments with regard to such signatures. The source of specimens from which sequencing data (eg, primary tumors vs

Fig. 1 – Association between FGFR3 mutations and response to treatment with atezolizumab in IMVigor 210 or nivolumab in CheckMate 275 cohorts. (A) Targeted exome sequencing data were available for 274 patients (Foundation One; Foundation Medicine) from the IMVigor 210 cohort, among whom 49 had tumors harboring FGFR3 mutations. (B) Whole exome sequencing data were available for 139 patients from the CheckMate 275 cohort, among whom 15 had tumors harboring FGFR3 mutations. Distribution of specific FGFR3 mutations among (C) 49 tumors in IMVigor 210 and (D) 15 tumors in CheckMate 275. (E) Objective response rate in patients with FGFR3-mutant versus wild-type tumors with atezolizumab in the IMVigor 210 cohort. The response rates (complete and partial responses) were 24% (95% CI: 14%, 39%) and 21% (95% CI: 16%, 27%) in FGFR3-mutant group and wild-type group, respectively (p = 0.8). (F) Objective response rate to nivolumab in the CheckMate 275 cohort. When considering only known FGFR3 hotspot mutations in the CheckMate 275 cohort, 12/139 (8.6%) harbored mutations and the objective response rate (complete and partial responses) in patients with FGFR3-mutant tumors was 20% (95% CI: 6%, 51%) versus 21% (95% CI: 15%, 29%) in patients with FGFR3 wild-type tumors (p = 0.2). All p values are based on the chi-square test. CI = confidence interval; CR = complete response; NE = not evaluable; PD = progression of disease; PR = partial response; SD = stable disease.
metastases, bladder vs upper urinary tract, etc.) and intratumoral heterogeneity were derived could potentially impact our results. Further, we observed a different prevalence of m\textit{FGFR3} in the two clinical trials, which may be at least in part related to technical differences in the next-generation sequencing approaches employed.

There are several implications of our findings: (1) Patients with m\textit{UC} harboring m\textit{FGFR3} should not be denied treatment with CPI. Despite prior analyses demonstrating an association between m\textit{FGFR3} and decreased T-cell infiltration, and hypothesis-generating data presented in our analysis highlighting at least one potential causative mechanism underlying such observations, there is currently no direct experimental or clinical evidence for \textit{FGFR3} signaling driving CPI resistance. (2) Clinical trials evaluating combinations with CPI should probe the balance of immunomodulatory effects of \textit{FGFR3} inhibition.

Several trials combining CPI with \textit{FGFR3} inhibitors have been initiated. Despite a potentially complex relationship between m\textit{FGFR3} and antitumor immunity, given that non-cross resistance of drugs with single-agent activity may underlie the benefit of most combination regimens [11], the finding that patients with m\textit{FGFR3} UC are responsive to CPI similarly to those with WT UC may provide an even greater pragmatic rationale for moving such combinations forward.

**Author contributions:** Matthew D. Galsky had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Galsky, Zhu, Wang. Acquisition of data: Wang, Gong, Saci, Szabo, Necchi, Siefker-Radtke, Pal, Plimack, Sharma. Analysis and interpretation of data: All authors. Drafting of the manuscript: Galsky, Zhu, Wang, Martini, Saci, Szabo. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Zhu, Wang, Szabo, Martini. Obtaining funding: Galsky. Administrative, technical, or material support: Galsky, Zhu. Supervision: Galsky, Zhu, Wang. Other: None.

**Financial disclosures:** Matthew D. Galsky certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Dr. Andrea Necchi reports grants and personal fees from Merck and Incyte; and personal fees from Bayer, BMS, Rainier Therapeutics, Clovis, Astra Zeneca, and Janssen, outside the submitted work. Matthew D. Galsky has served on an advisory board for Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas, Genentech, Bristol-Myers Squibb, Novartis, Pfizer,

---

**Fig. 2** – Relationship between \textit{FGFR3} mutations and previously identified independent predictors of response to PD-1/PD-L1 blockade. Compared with wild-type tumors, neoplasms with \textit{FGFR3} mutations in the IMVigor 210 cohort were associated with (A) lower CD8 T-cell gene signature expression (estimated difference of CD8 effector expression level \(-2.34 [95\% \text{ CI}: \quad -3.14, -1.54; \quad p < 0.001])\), (B) no statistically significant difference in tumor mutational burden (estimated difference of mutation burden: \(1.88 [95\% \text{ CI}: \quad 2.09, 5.86; \quad p = 0.7]\)), and (C) lower fibroblast TGF-\(\beta\) response signature (F-TBRS) (estimated difference of F-TBRS: \(-2.43 [95\% \text{ CI}: \quad -3.21, -1.65; \quad p = 0.01]\)) and (D) EMT/Stroma core signature expression (estimated difference of EMT/Stroma core: \(-3.63 [95\% \text{ CI}: \quad -4.62, -2.64; \quad p = 0.01]\)). The balance of CD8 T-cell gene signature expression and expression of the stromal signatures was either (E) not significantly different in the \textit{FGFR3}-mutant versus wild-type tumors (F-TBRS; estimated difference 0.09 [95\% CI: \(-0.79, 0.97; \quad p = 0.8\)]) or (F) higher in \textit{FGFR3}-mutant versus wild-type tumors (EMT/Stroma-core signature; estimated difference: \(1.28 [95\% \text{ CI}: \quad 0.42, 2.14; \quad p = 0.01]\)). Gene expression is log2 transformed. All \(p\) values are based on the Wilcoxon test. CI = confidence interval; Mut = mutant; TGF-\(\beta\) = transforming growth factor beta; WT = wild type.
EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, and Inovio Pharmaceuticals; has received research funding from Janssen, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, and Genentech/Roche; and is a cofounder of RAPPTA Therapeutics.

**Funding/Support and role of the sponsor:** None.

**Appendix A. Supplementary data**

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.eururo.2019.06.025.

**References**


